ADMA Biologics Faces Class Action Over Alleged Securities Fraud

The complaint filed against the NASDAQ-listed firm centers on accusations that ADMA Biologics masked its true performance through deceptive tactics. According to the court filings, the company failed to disclose a related party transaction and engaged in channel stuffing to artificially inflate its reported sales activity. These actions allegedly left shareholders with a distorted view of the company's operational reality throughout the designated class period.

The DJS Law Group is currently seeking investors who suffered financial losses to act as potential lead plaintiffs. While the deadline to file for this role is August 10, 2026, the firm notes that individual investors do not need to be appointed as lead plaintiffs to participate in any eventual recovery. The lawsuit specifically cites violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.